BREAKING NEWS: New treatment for pulmonary fibrosis
Nintedanib, an anti-fibrotic drug used to slow progression of idiopathic pulmonary fibrosis (IPF) has been shown to work for many other types of progressive pulmonary fibrosis.
The results of a 15 country clinical trial were announced today at the European Respiratory Society (ERS) Congress in Madrid. Scientists found that lung function for patients who took nintedanib declined more slowly than those who took a placebo. The rate of decline in the FVC (forced vital capacity) was −80.8 ml per year with nintedanib and −187.8 ml per year with placebo, a difference of -107 ml per year.
These results bring hope of a new treatment for patients of diseases including: hypersensitivity pneumonitis, autoimmune interstitial lung disease such as rheumatoid arthritis-associated ILD, sarcoidosis, systemic sclerosis-associated ILD, mixed connective tissues disease-associated ILD, idiopathic non-specific interstitial pneumonia, unclassified idiopathic interstitial pneumonia and some others.
The results will now be appraised by the National Institute for Health and Care Excellence (NICE), who will decide whether the drug can be prescribed to this new group of patients in the UK.
APF Chair, Steve Jones, who is at the ERS said: “This is excellent news. The results give hope to a large number of patients with progressive lung fibrosis, who cannot currently be prescribed anti-fibrotic medicines”.
The results have been published in the New England Journal of Medicine – https://www.nejm.org/ .